About NEUROPATHIX
NEUROPATHIX is a company based in Doylestown (United States) founded in 2010 by Thoma Kikis.. The company has 7 employees as of December 31, 2020. NEUROPATHIX offers products and services including KLS-13019 and Patented NCEs. NEUROPATHIX operates in a competitive market with competitors including GW Pharma, IGC Pharma, MIRA Pharmaceuticals, Agrithera and Avata Biosciences, among others.
- Headquarter Doylestown, United States
- Employees 7 as on 31 Dec, 2020
- Founders Thoma Kikis
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neuropathix, Inc.
-
Annual Revenue
$183.48 K0as on Dec 31, 2021
-
Net Profit
$-3.56 M22as on Dec 31, 2021
-
EBITDA
$-2.94 M34as on Dec 31, 2021
-
Latest Funding Round
$1.21 M (USD), Post-IPO
Feb 23, 2021
-
Investors
-
Employee Count
7
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NEUROPATHIX
NEUROPATHIX offers a comprehensive portfolio of products and services, including KLS-13019 and Patented NCEs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cannabinoid-inspired molecule for treating inflammation and pain effectively.
Novel agents targeting neurological disorders and oxidative stress.
Unlock access to complete
Unlock access to complete
Funding Insights of NEUROPATHIX
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $1.2M
-
First Round
First Round
(23 Feb 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Post-IPO - NEUROPATHIX | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by NEUROPATHIX
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NEUROPATHIX
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neuropathix Comparisons
Competitors of NEUROPATHIX
NEUROPATHIX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GW Pharma, IGC Pharma, MIRA Pharmaceuticals, Agrithera and Avata Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| domain | founded_year | HQ Location |
Cannabinoid-based therapeutics for chronic pain and anxiety are developed.
|
|
| domain | founded_year | HQ Location |
Cannabis-based therapeutics are developed for pain and neurological disorders.
|
|
| domain | founded_year | HQ Location |
Develops synthetic cannabinoids for epilepsy and schizophrenia treatments through innovative formulations.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neuropathix
Frequently Asked Questions about NEUROPATHIX
When was NEUROPATHIX founded?
NEUROPATHIX was founded in 2010 and raised its 1st funding round 11 years after it was founded.
Where is NEUROPATHIX located?
NEUROPATHIX is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Who is the current CEO of NEUROPATHIX?
Dean Petkanas is the current CEO of NEUROPATHIX.
How many employees does NEUROPATHIX have?
As of Dec 31, 2020, the latest employee count at NEUROPATHIX is 7.
What is the annual revenue of NEUROPATHIX?
Annual revenue of NEUROPATHIX is $183.48K as on Dec 31, 2021.
What does NEUROPATHIX do?
Therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain are developed by NEUROPATHIX, founded in 2010 and based in Doylestown, United States. Preclinical drug discovery and development of synthetic cannabidiol-inspired molecules form the core operations within the biotechnology sector. Research efforts address neurodegenerative diseases, oxidative stress conditions, and neuropathic pain disorders through a dedicated product platform.
Who are the top competitors of NEUROPATHIX?
NEUROPATHIX's top competitors include IGC Pharma, MIRA Pharmaceuticals and GW Pharma.
What products or services does NEUROPATHIX offer?
NEUROPATHIX offers KLS-13019 and Patented NCEs.